JavaScript Required

Jumpseat Aerospace News requires JavaScript to function. Please enable JavaScript in your browser settings to continue.

BioOrbit Secures £9.8M Seed Funding

May 1, 2026

1 min read

Key Takeaways

BioOrbit raises £9.8M seed round.
Funding to ramp up space-drug manufacturing.
Expanding US market presence.
Hiring Redwire veterans for business development.

Silver membership required Upgrade to Silver to access Key Takeaways.

Upgrade

Strategic Implications

This investment may indicate growing interest in leveraging microgravity for pharmaceutical manufacturing, which could lead to more accessible treatments for patients. BioOrbit's expansion suggests a potential shift in the space industry towards life sciences applications, which may attract new investors and partners.

Silver membership required Upgrade to Silver to access Strategic Implications.

Upgrade

What Happened

London-Based Startup Expands Space-Drug Manufacturing Capabilities

London-based BioOrbit has announced a £9.8M seed round to expand its space-drug manufacturing capabilities and presence in the US market. The company aims to reformulate existing cancer treatments for self-administration by patients, using its autonomous manufacturing unit BOX. With the new funding, BioOrbit plans to transition from early-stage demonstrations to industrial capacity and open a US office, as reported by Payload Space.

Source

Companies Mentioned